Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer
- Conditions
- First Posted Date
- 2003-11-04
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- University of Leicester
- Registration Number
- NCT00004206
- Locations
- 🇬🇧
University Hospitals of Leicester, Leicester, England, United Kingdom
Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery
- Conditions
- First Posted Date
- 2003-10-15
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00015886
- Locations
- 🇺🇸
Cancer Centers of the Carolinas, Greenville, South Carolina, United States
🇺🇸East Carolina University School of Medicine, Greenville, North Carolina, United States
🇺🇸Palmetto Hematology/Oncology Associates, Spartanburg, South Carolina, United States
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2200
- Registration Number
- NCT00070122
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 460
- Registration Number
- NCT00070213
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
🇬🇧Cookridge Hospital, Leeds, England, United Kingdom
🇬🇧Clinical Trials and Research Unit of the University of Leeds, Leeds, England, United Kingdom
S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00070434
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 43
- Registration Number
- NCT00069953
- Locations
- 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸Hubert H. Humphrey Cancer Center at North Memorial Medical Center, Robbinsdale, Minnesota, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-25
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1691
- Registration Number
- NCT00003594
- Locations
- 🇺🇸
Hematology Oncology Associates of Illinois - Lake Shore Dr, Chicago, Illinois, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer
- Conditions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 88
- Registration Number
- NCT00068744
- Locations
- 🇷🇸
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
🇧🇪Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium
🇧🇪Cazk Groeninghe - Campus Maria's Voorzienigheid, Kortrijk, Belgium
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00068575
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
- Conditions
- Rectal Signet Ring Cell AdenocarcinomaStage IIA Rectal Cancer AJCC v7Stage IIIA Rectal Cancer AJCC v7Stage IIIB Rectal Cancer AJCC v7Rectal Mucinous AdenocarcinomaRecurrent Rectal CarcinomaStage IIC Rectal Cancer AJCC v7Stage IIB Rectal Cancer AJCC v7Stage IVA Rectal Cancer AJCC v7Stage IIIC Rectal Cancer AJCC v7
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 225
- Registration Number
- NCT00068692
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.